FDA approves BRINSUPRI as first treatment for non-cystic fibrosis bronchiectasis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/1/2026

1. MDT
2. SPY
3. ENOV
4. AON
5. AZN
6. BLSM
7. GRMN
8. GPRO
9. KRMN
10. USO

Go back to FDA approves BRINSUPRI as first treatment for non-cystic fibrosis bronchiectasis

FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

August 12, 2025 11:35 AM EDT

Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage

BRINSUPRI 10 mg and 25 mg Doses Approved for the Treatment of NCFB

BRINSUPRI, a First-in-Class DPP1 Inhibitor Targeting Neutrophilic Inflammation, Is Available by Prescription Through a Comprehensive Specialty Pharmacy Network

Insmed to Host Investor Conference Call Today at 12:00 PM ET... More